| Invitae Makes a Precision Oncology Push With $886M Deal for ArcherDx | Frank Vinluan | 06/22/20 | San Francisco |
| Melinta Expands Antibiotics Lineup With $39M Tetraphase Acquisition | Frank Vinluan | 06/09/20 | New York |
| Bio Roundup: ASCO Opens, Merck Takes On COVID, Evofem’s Approval & More | Sarah de Crescenzo | 05/29/20 | National |
| Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More | Frank Vinluan | 04/24/20 | National |
| Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More | Sarah de Crescenzo | 03/06/20 | National |
| Melinta’s Chapter 11 Auction Draws No Bids, Deerfield to Get Assets | Frank Vinluan | 03/04/20 | New York |
| Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More | Frank Vinluan | 09/27/19 | National |
| Oncorus Adds $79.5M to Steer Cancer-Fighting Virus to Human Testing | Frank Vinluan | 08/21/19 | Boston |
| WI Watchlist: Microsoft, Exact Sciences, Shine & MKE Tech Hub | Jeff Bauter Engel | 07/03/19 | Wisconsin |
| NorthStar Secures $75M+ as Medical Radioisotope Competition Revs Up | Jeff Bauter Engel | 04/24/19 | Wisconsin |
| Bio Roundup: Golumbeski’s Legacy, CRISPR Moratorium, Rebate Week & More | Frank Vinluan | 03/15/19 | National |
| Clinical Analytics Platform TriNetX Raises $40M to Speed Drug Trials | Brian Dowling | 03/13/19 | Boston |
| Ribon Raises $65M to Pursue PARP-Blocking Pills for Cancer | Corie Lok | 01/04/19 | Boston |
| InCarda Breathes In $42M for Clinical Tests of Inhalable Heart Drug | Frank Vinluan | 11/08/18 | San Francisco |
| Mirum Pharmaceuticals Launches with $120M to Advance Liver Drugs | Sarah de Crescenzo | 11/07/18 | San Diego |
| Phoenix Plans to Build New HQ After Inking $15M in New Contracts | Jeff Buchanan | 08/31/18 | Wisconsin |
| Fresh Off GSK Deal, Gene Therapy Startup Orchard Bags Another $150M | Ben Fidler | 08/13/18 | Boston |
| Alector Snags $133M to Activate Immune Cells Against Neurodegeneration | Bernadette Tansey | 07/25/18 | San Francisco |
| The Biggest Wisconsin Venture Round of the Decade… Didn’t Happen | Jeff Buchanan | 06/26/18 | Wisconsin |
| Fresh Off $25M Raise, Generation Adds $100M For Next-Gen Gene Therapy | Ben Fidler | 02/27/18 | Boston |
| MSOE, Noncompetes, NASA, & More: This Week’s Wisconsin Watchlist | Jeff Buchanan | 10/27/17 | Wisconsin |
| Phoenix Pulls in $12M to Fuel Growth of Neutron Generators | Jeff Buchanan | 10/26/17 | Wisconsin |
| Bio Roundup: Light For Spark, California Drug Law, IPO Queue & More | Alex Lash | 10/13/17 | National |
| Homology Med Bags $83.5M More, Fueling Push For Gene Editing Twist | Ben Fidler | 08/01/17 | Boston |
| Scott Gottlieb On Tap to Lead FDA, and Biopharma Exhales | Ben Fidler | 03/10/17 | National |
| Harvard’s Verdine Aims to Retire, Become Full-Time FogPharma CEO | Ben Fidler | 02/23/17 | Boston |
| Rhythm Raises $41M to Bankroll Late-Stage Push For Obesity Drug | David Holley | 02/16/17 | Boston |
| Austin Biotech Xeris Names Edick CEO, Raises $41M in Series C Round | Angela Shah | 01/10/17 | Texas |
| NY Bio Surge Continues as De Blasio Unveils $500M, 10-Year Life Sci Plan | Ben Fidler | 12/13/16 | New York |
| Celldex, Aiming For More Cancer Drug Combos, Pays $62.5M For Kolltan | Ben Fidler | 11/01/16 | New York |
